57 completed. 57 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 57 | Completed 57 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa Mirikizumab, Vedolizumab - Ulcerative Colitis | Phase 4 | Completed | Showa Inan General Hospital | 100 | 2024-07-20 | 2025-10-20 |
| A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease Breast Milk Sampling, Risankizumab - Inflammatory Bowel Disease | Phase 4 | Completed | AbbVie | 10 | 2024-04-24 | 2026-04-20 |
| Role of Roflumilast in Ulcerative Colitis Roflumilast 500 MCG Oral Tablet [DALIRESP], amino salicylic acid - Ulcerative Colitis | Phase 4 | Completed | Tanta University | 52 | 2023-02-01 | 2025-01-28 |
| ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA 5-ASA - Ulcerative Colitis | Phase 4 | Completed | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | 200 | 2023-01-17 | 2024-03-21 |
| Can Vitamin D Replacement Correct Chronic Disease Anemia? Cholecalciferol (Vit D3) - Vitamin D, Iron Deficiency and Overload | Phase 4 | Completed | Gazi University | 43 | 2022-09-30 | 2026-06-29 |
| Carotegrast Methyl in Ulcerative Colitis Carotegrast methyl - Ulcerative Colitis | Phase 4 | Completed | Takayuki Yamamoto | 50 | 2022-06-01 | 2025-04-02 |
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events Tofacitinib, Infliximab Adalimumab y Golimumab - Ulcerative Colitis, Thromboembolism | Phase 4 | Completed | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 32 | 2022-04-01 | 2026-09-18 |
| The Nordic IBD Treatment Strategy Trial Top down treatment if patient at high risk - Inflammatory Bowel Diseases, Ulcerative Colitis | Phase 4 | Completed | Region Örebro County | 300 | 2022-02-07 | 2025-12-10 |
| Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis Infliximab, Vedolizumab, Mesalazine - Ulcerative Colitis, Efficacy, Self | Phase 4 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 438 | 2022-01-15 | 2026-04-29 |
| A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease Vedolizumab IV - Ulcerative Colitis, Crohn Disease | Phase 4 | Completed | Takeda | 150 | 2021-12-08 | 2025-02-12 |
| Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis Fecal microbiota transplantation - Ulcerative Colitis | Phase 4 | Completed | McMaster University | 6 | 2021-05-01 | 2024-11-20 |
| Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis Golimumab Prefilled Syringe - Ulcerative Colitis | Phase 4 | Completed | David Drobne | 27 | 2021-04-07 | 2024-07-30 |
| Determination of the Optimal Treatment Target in Ulcerative Colitis Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C - Colitis, Ulcerative | Phase 4 | Completed | Alimentiv Inc. | 672 | 2020-02-18 | 2026-09-10 |
| The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis Vedolizumab - Ulcerative Colitis (UC) | Phase 4 | Completed | Second Affiliated Hospital of Wenzhou Medical University | 898 | 2020-01-01 | 2026-02-10 |
| Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Completed | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 180 | 2019-09-10 | 2025-03-17 |
| Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Shingrix - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Completed | University of Wisconsin, Madison | 33 | 2019-05-28 | 2025-04-02 |
| EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis Infliximab, Vedolizumab Injection - Ulcerative Colitis | Phase 4 | Completed | Rennes University Hospital | 151 | 2019-01-04 | 2025-06-24 |
| Ultra-proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease infliximab therapeutic drug monitoring - Crohn Disease, Ulcerative Colitis | Phase 4 | Completed | Imelda GI Clinical Research Center | 187 | 2018-06-01 | 2021-08-05 |
| Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment. E. coli Nissle 1917 (Mutaflor®), Placebo - Ulcerative Colitis | Phase 4 | Completed | Kangbuk Samsung Hospital | 134 | 2018-03-16 | 2021-07-21 |
| Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Vedolizumab - Colitis, Ulcerative, Crohn's Disease | Phase 4 | Completed | Takeda | 11 | 2017-11-29 | 2021-01-08 |
Showing 20 of 57. Sign in to see all of them.
Colitis, Ulcerative (56) · Crohn Disease (19) · Inflammatory Bowel Diseases (18) · Breast Feeding (2) · Iron Deficiencies (2) · Abdominal Pain (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Charcot-Marie-Tooth disease, Type 1C (1) · Diarrhea (1) · Flatulence (1) · Gastrointestinal Hemorrhage (1) · Hepatitis A (1) · Herpes Zoster (1)
Colonic Diseases (57) · Digestive System Diseases (57) · Gastroenteritis (57) · Gastrointestinal Diseases (57) · Intestinal Diseases (57) · Inflammatory Bowel Diseases (38) · Pathological Conditions, Signs and Symptoms (4) · Behavior (3) · Feeding Behavior (2) · Immune System Diseases (2) · Infections (2) · Iron Metabolism Disorders (2) · Metabolic Diseases (2) · Neoplasms (2)
Infliximab (10) · Mesalamine (10) · vedolizumab (9) · golimumab (6) · Hydrocortisone (2) · tofacitinib (2) · 13-valent pneumococcal vaccine (1) · AJM300 (1) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Amoxicillin (1) · Azathioprine (1) · CT-P13 (1) · Calcineurin Inhibitors (1) · Cholecalciferol (1)
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (3) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (3) · Merck Sharp & Dohme LLC (3) · Takeda (3) · Asan Medical Center (2) · Shire (2) · AbbVie (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Alimentiv Inc. (1) · Amsterdam UMC, location VUmc (1) · Austin Health (1) · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW (1) · Connecticut Children's Medical Center (1) · David Drobne (1) · Diakonhjemmet Hospital (1)
United States (15) · France (8) · Belgium (7) · Canada (7) · Spain (5) · United Kingdom (5) · Israel (4) · Italy (4) · Netherlands (4) · South Korea (4) · China (3) · Australia (2) · Denmark (2) · Hungary (2) · India (2)
Arie Levine, MD (2) · Andreas M Petersen, MD, ph.d. (1) · Axel Dignass, Professor (1) · Batia Weiss, MD (1) · Catherine Reenaers, MD, PhD (1) · Dan Turner, MD, PhD (1) · David Drobne, MD, PhD (1) · David S Rampton, DPhil, FRCP (1) · Edouard Louis, MD, PhD (1)
PMID 21837775, PMID 23063316, PMID 24284413, PMID 24793028, PMID 25193617, PMID 26848182, PMID 27932449, PMID 28053054, PMID 28286194, PMID 28502609, PMID 28939374, PMID 29361097, PMID 29920582, PMID 30002864, PMID 30294708, PMID 30731474, PMID 30762274, PMID 30935734, PMID 30989180, PMID 31373712, PMID 31516554, PMID 32506695, PMID 32801008, PMID 32804854, PMID 32965617, PMID 33290108, PMID 33544318, PMID 33971650, PMID 35272029, PMID 36068716, PMID 37951560, PMID 39089718, PMID 39236736, PMID 39586616, PMID 39794921, PMID 40013523, PMID 40995992
2014 (4), 2009 (1), 2017 (1), 2018 (1), 2019 (1), K24DK078228 (1), U34DK090804 (1)